These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 24503785)

  • 21. Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy.
    Grossfeld GD; Small EJ; Lubeck DP; Latini D; Broering JM; Carroll PR
    Urology; 2001 Aug; 58(2 Suppl 1):56-64. PubMed ID: 11502450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RE: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Carlsson S; Roobol MJ; Schröder FH; Hugosson J; Auvinen A
    J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24771874
    [No Abstract]   [Full Text] [Related]  

  • 23. Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Walsh PC
    J Natl Cancer Inst; 2014 Feb; 106(2):djt432. PubMed ID: 24399847
    [No Abstract]   [Full Text] [Related]  

  • 24. [Diagnosis and treatment of early prostate cancer].
    Kaprin AD; Khalil Farzat M; Gafanov RA; Kostin AA
    Vopr Onkol; 2009; 55(3):382-5. PubMed ID: 19670743
    [No Abstract]   [Full Text] [Related]  

  • 25. Controversies in prostate cancer radiotherapy: consensus development.
    Lukka H; Warde P; Pickles T; Morton G; Brundage M; Souhami L;
    Can J Urol; 2001 Aug; 8(4):1314-22. PubMed ID: 11564274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Castration resistant prostate cancer 2011].
    Miller K
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hormone therapy can wait in PSA-only relapse.
    Schmidt C
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25122737
    [No Abstract]   [Full Text] [Related]  

  • 28. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Tiguert R; Rigaud J; Lacombe L; Laverdière J; Fradet Y
    J Urol; 2003 Aug; 170(2 Pt 1):447-50. PubMed ID: 12853796
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate carcinoma.
    Lorusso V
    Tumori; 2002; 88(1 Suppl 1):S125-7. PubMed ID: 11989904
    [No Abstract]   [Full Text] [Related]  

  • 32. Current management of advanced and castration resistant prostate cancer.
    Gomella LG; Petrylak DP; Shayegan B
    Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality.
    Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR
    J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society.
    Pegurri L; Buglione M; Girelli G; Guarnieri A; Meattini I; Ricardi U; Mangoni M; Gabriele P; Bellavita R; Krengli M; Bonetta A; Cagna E; Bunkheila F; Borghesi S; Signor M; Di Marco A; Bertoni F; Stefanacci M; Gatta R; De Bari B; Magrini SM
    Tumori; 2014; 100(1):31-7. PubMed ID: 24675488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Prostate brachytherapy: oncological and functional results after 400 cases].
    Gastaldi E; Chiono L; Gallo F; Giberti C
    Urologia; 2014; 81 Suppl 23():S15-9. PubMed ID: 24665030
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends in the use of androgen deprivation in prostate cancer.
    Salminen EK; Wickström JE; Vahlberg T; Duchesne GM
    Acta Oncol; 2004; 43(4):382-7. PubMed ID: 15303500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radiation Therapy Oncology Group P-0014: a phase 3 randomized study of patients with high-risk hormone-naive prostate cancer: androgen blockade with 4 cycles of immediate chemotherapy versus androgen blockade with delayed chemotherapy.
    Pienta KJ;
    Urology; 2003 Dec; 62 Suppl 1():95-101. PubMed ID: 14747047
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
    Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
    J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prostate cancer screening: biases and the need for consensus.
    Brawley OW
    J Natl Cancer Inst; 2013 Oct; 105(20):1522-4. PubMed ID: 24092919
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.